New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›MK-677 (Ibutamoren) vs Pinealon

MK-677 (Ibutamoren) vs Pinealon

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
MK-677 (Ibutamoren)
Cognitive EnhancementAnti-Aging & Longevity
Pinealon
Summary
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
Half-Life
24 hours
Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
Admin Route
Oral
SubQ, Oral, Intranasal
Research
—
—
Typical Dose
10–25 mg
5–10 mg (oral) or 50–100 mcg (SC)
Frequency
Once daily
Once daily for 10 days
Key Benefits
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
  • Neuroprotection against oxidative stress and hypoxia
  • Promotes neuronal regeneration and repair
  • Improves memory and cognitive function
  • Enhances sleep quality via melatonin regulation
  • Anti-aging effects on brain cells
  • May slow cognitive decline in neurodegeneration
  • Improves cerebrovascular circulation
  • Reduces neuroinflammation
Side Effects
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
  • Excellent safety profile in clinical use
  • Rare: mild drowsiness
  • Transient mild headache at initiation
  • Injection site reaction (SC)
Stacks With
—
—